A Phase 1 interventional study of Naproxen Sodium (Aleve, BAY117031) and Acetylsalicylic Acid (Aspirin, BAYE4465) in Hematology, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-15.
Sponsored by Bayer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
Drug: Naproxen Sodium (Aleve, BAY117031) · Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Naproxen sodium 220 mg qd or bid
ASA 81 mg qd
Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration
Inhibition of serum TXB2 at specified time point was calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% Confidence Interval (CI) were calculated.
Time frame: At hour 24 on Day 16 post treatment
Inhibition of Serum TXB2 on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours (Except at 24 Hours on Day 16) Post IR ASA 81 mg Administration
Inhibition of serum TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.
Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19 (except 24 hours on Day 16)
Inhibition of Arachidonic Acid (AA)-Induced Platelet Aggregation on Days 7, 16, 17, and 19 at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration
Inhibition of AA-induced platelet aggregation at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated. The platelet aggregation change-from-baseline scores range broadly in large part due to inclusion of participants with low baseline platelet aggregation scores.
Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19
Inhibition of TXB2 Using Platelet-rich Plasma (PRP) on Days 7, 16, 17, and 19 of the In-house Treatment Period at 1, 3, 6, 12, 18, and 24 Hours Post IR ASA 81 mg Administration
Inhibition of plasma TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.
Time frame: At 1, 3, 6, 12, 18, and 24 hours on Days 7, 16, 17, and 19
The study was conducted at a single site in United States between 16-Feb-2015 (first patient first visit) and 08-May-2015 (last patient last visit).
| Milestone | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid |
|---|---|---|---|---|---|---|
| Started | 17 | 17 | 17 | 17 | 17 | 17 |
| Completed | 17 | 17 | 17 | 17 | 17 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Inhibition of serum TXB2 at specified time point was calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% Confidence Interval (CI) were calculated.
| percentage | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid |
|---|---|---|---|---|---|---|
| Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration | 93.09 (91.50 to NA) | 87.71 (85.51 to NA) | 92.87 (91.24 to NA) | 98.72 (98.49 to NA) | 95.35 (94.14 to NA) | 95.65 (94.74 to NA) |
Inhibition of serum TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.
| percentage | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid |
|---|---|---|---|---|---|---|
| Day 7 at 1 hour | 99.86 (99.82 to NA) | 99.83 (99.81 to NA) | 99.69 (99.63 to NA) | 99.67 (99.60 to NA) | 99.91 (99.87 to NA) | 99.84 (99.81 to NA) |
| Day 7 at 3 hour | 99.84 (99.79 to NA) | 99.79 (99.76 to NA) | 99.54 (99.46 to NA) | 99.66 (99.58 to NA) | 99.86 (99.81 to NA) | 99.80 (99.77 to NA) |
| Day 7 at 6 hour | 99.69 (99.58 to NA) | 99.67 (99.60 to NA) | 99.44 (99.34 to NA) | 99.48 (99.36 to NA) | 99.75 (99.63 to NA) | 99.70 (99.65 to NA) |
| Day 7 at 12 hour | 99.59 (99.46 to NA) | 99.48 (99.42 to NA) | 99.12 (98.98 to NA) | 99.31 (99.17 to NA) | 99.68 (99.57 to NA) | 99.63 (99.56 to NA) |
| Day 7 at 18 hour | 99.18 (99.01 to NA) | 99.18 (99.04 to NA) | 99.76 (99.71 to NA) | 98.86 (98.68 to NA) | 99.39 (99.19 to NA) | 99.70 (99.64 to NA) |
| Day 7 at 24 hour | 99.01 (98.76 to NA) | 99.55 (99.43 to NA) | 97.78 (96.51 to NA) | 98.71 (98.46 to NA) | 99.23 (99.00 to NA) | 99.80 (99.75 to NA) |
| Day 16 at 1 hour | 99.06 (98.79 to NA) | 98.38 (98.10 to NA) | 98.32 (98.09 to NA) | 99.71 (99.64 to NA) | 99.28 (99.08 to NA) | 98.81 (98.59 to NA) |
| Day 16 at 3 hour | 98.80 (98.49 to NA) | 97.67 (97.41 to NA) | 98.02 (97.68 to NA) | 99.68 (99.60 to NA) | 99.19 (99.00 to NA) | 98.53 (98.23 to NA) |
| Day 16 at 6 hour | 97.69 (97.21 to NA) | 96.26 (95.70 to NA) | 97.40 (97.03 to NA) | 99.55 (99.45 to NA) | 98.43 (98.05 to NA) | 97.51 (97.10 to NA) |
| Day 16 at 12 hour | 96.59 (95.67 to NA) | 92.71 (91.13 to NA) | 96.31 (95.68 to NA) | 99.42 (99.29 to NA) | 97.84 (97.10 to NA) | 95.38 (94.13 to NA) |
| Day 16 at 18 hour | 94.19 (93.04 to NA) | 92.23 (90.24 to NA) | 95.68 (94.62 to NA) | 99.01 (98.85 to NA) | 96.45 (95.43 to NA) | 97.73 (97.28 to NA) |
| Day 17 at 1 hour | 95.71 (94.31 to NA) | 94.63 (93.66 to NA) | 95.56 (94.69 to NA) | 99.70 (99.64 to NA) | 97.42 (96.88 to NA) | 96.95 (96.30 to NA) |
| Day 17 at 3 hour | 95.49 (94.38 to NA) | 92.79 (91.36 to NA) | 96.43 (95.89 to NA) | 99.68 (99.60 to NA) | 96.96 (96.33 to NA) | 95.92 (95.03 to NA) |
| Day 17 at 6 hour | 93.55 (91.86 to NA) | 90.91 (89.21 to NA) | 95.64 (94.92 to NA) | 99.52 (99.41 to NA) | 95.31 (94.32 to NA) | 93.91 (92.61 to NA) |
| Day 17 at 12 hour | 92.54 (91.08 to NA) | 91.15 (89.80 to NA) | 94.13 (93.08 to NA) | 99.30 (99.13 to NA) | 94.74 (93.62 to NA) | 92.60 (90.92 to NA) |
| Day 17 at 18 hour | 89.44 (87.48 to NA) | 87.19 (85.43 to NA) | 94.23 (93.42 to NA) | 98.95 (98.76 to NA) | 93.42 (92.27 to NA) | 88.14 (85.42 to NA) |
| Day 17 at 24 hour | 89.05 (86.86 to NA) | 83.67 (81.77 to NA) | 90.39 (88.57 to NA) | 98.70 (98.48 to NA) | 91.40 (89.21 to NA) | 84.27 (80.66 to NA) |
| Day 19 at 1 hour | 98.35 (97.86 to NA) | 97.89 (97.45 to NA) | 98.89 (98.64 to NA) | 99.69 (99.62 to NA) | 98.16 (97.74 to NA) | 94.06 (92.59 to NA) |
| Day 19 at 3 hour | 98.52 (98.02 to NA) | 97.90 (97.46 to NA) | 99.05 (98.93 to NA) | 99.64 (99.55 to NA) | 98.27 (97.92 to NA) | 94.44 (92.92 to NA) |
| Day 19 at 6 hour | 98.26 (97.78 to NA) | 97.43 (96.73 to NA) | 98.98 (98.81 to NA) | 99.50 (99.39 to NA) | 97.84 (97.34 to NA) | 93.25 (91.11 to NA) |
| Day 19 at 12 hour | 97.67 (96.95 to NA) | 96.90 (96.06 to NA) | 98.77 (98.57 to NA) | 99.26 (99.09 to NA) | 97.33 (96.70 to NA) | 92.00 (89.44 to NA) |
| Day 19 at 18 hour | 97.21 (96.40 to NA) | 96.29 (95.40 to NA) | 98.52 (98.27 to NA) | 98.88 (98.67 to NA) | 96.62 (95.86 to NA) | 90.94 (88.41 to NA) |
| Day 19 at 24 hour | 97.04 (96.13 to NA) | 96.16 (95.25 to NA) | 97.98 (97.72 to NA) | 98.49 (98.19 to NA) | 96.01 (94.86 to NA) | 90.67 (88.25 to NA) |
Inhibition of AA-induced platelet aggregation at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated. The platelet aggregation change-from-baseline scores range broadly in large part due to inclusion of participants with low baseline platelet aggregation scores.
| percentage | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid |
|---|---|---|---|---|---|---|
| Day 7 at 1 hour | 58.60 ± 58.893 | 12.78 ± 139.818 | 5.55 ± 306.389 | 87.73 ± 8.777 | 64.14 ± 40.389 | 30.45 ± 182.916 |
| Day 7 at 3 hour | -121.76 ± 630.765 | 12.86 ± 144.823 | 10.80 ± 280.405 | 79.16 ± 29.318 | 75.89 ± 24.067 | 18.99 ± 222.208 |
| Day 7 at 6 hour | 61.74 ± 63.400 | 1.70 ± 168.415 | -3.29 ± 331.881 | 78.20 ± 33.051 | 73.69 ± 31.859 | 26.91 ± 183.636 |
| Day 7 at 12 hour | 36.41 ± 162.350 | 28.54 ± 113.063 | -17.95 ± 275.811 | 80.81 ± 33.244 | 76.02 ± 26.733 | 17.11 ± 249.918 |
| Day 7 at 18 hour | 62.36 ± 68.382 | 25.27 ± 119.755 | 11.96 ± 280.718 | 78.50 ± 37.671 | 38.58 ± 138.715 | -151.06 ± 863.434 |
| Day 7 at 24 hour | 80.60 ± 26.517 | 46.31 ± 91.924 | 41.29 ± 178.089 | 89.12 ± 18.535 | 77.61 ± 29.401 | 44.02 ± 157.466 |
| Day 16 at 1 hour | 68.96 ± 39.662 | 24.15 ± 114.782 | 29.25 ± 229.744 | 86.12 ± 21.728 | 62.67 ± 45.474 | 45.12 ± 141.196 |
| Day 16 at 3 hour | 75.25 ± 42.568 | 51.22 ± 74.825 | 33.12 ± 203.704 | 85.92 ± 21.762 | 83.51 ± 21.986 | 37.09 ± 170.694 |
| Day 16 at 6 hour | 74.45 ± 42.678 | 61.20 ± 63.333 | 62.32 ± 100.840 | 81.36 ± 37.422 | 82.55 ± 17.893 | 81.07 ± 26.570 |
| Day 16 at 12 hour | 79.88 ± 26.425 | 70.98 ± 51.499 | 11.16 ± 254.042 | 81.38 ± 31.472 | 79.51 ± 21.218 | 53.04 ± 118.315 |
| Day 16 at 18 hour | 73.86 ± 36.769 | 74.07 ± 40.473 | 35.43 ± 204.054 | 85.19 ± 25.762 | 71.93 ± 52.602 | 71.64 ± 52.123 |
| Day 16 at 24 hour | 67.47 ± 37.467 | 64.26 ± 51.050 | 15.96 ± 281.846 | 85.25 ± 18.848 | 73.73 ± 32.648 | 51.40 ± 116.489 |
| Day 17 at 1 hour | 76.23 ± 30.966 | 56.77 ± 63.792 | -452.48 ± 2088.027 | 83.53 ± 25.476 | 82.13 ± 19.364 | 33.64 ± 197.114 |
| Day 17 at 3 hour | 78.48 ± 27.969 | 46.16 ± 79.122 | 21.74 ± 255.742 | 83.48 ± 25.466 | 75.15 ± 30.948 | 48.27 ± 117.511 |
| Day 17 at 6 hour | 76.46 ± 36.017 | 69.16 ± 43.503 | 37.52 ± 204.341 | 83.48 ± 25.514 | 74.61 ± 38.546 | 52.03 ± 131.415 |
| Day 17 at 12 hour | 83.17 ± 20.398 | 86.40 ± 17.991 | -24.72 ± 408.994 | 86.00 ± 17.935 | 82.37 ± 27.172 | 67.55 ± 79.461 |
| Day 17 at 18 hour | 82.30 ± 22.570 | 68.65 ± 45.824 | 31.96 ± 178.297 | 83.71 ± 25.383 | 71.35 ± 31.709 | 41.51 ± 144.334 |
| Day 17 at 24 hour | 78.66 ± 36.988 | 70.84 ± 46.622 | 53.24 ± 103.247 | 85.43 ± 25.873 | 82.13 ± 29.286 | 87.02 ± 23.703 |
| Day 19 at 1 hour | 64.06 ± 64.304 | 41.10 ± 103.816 | 21.46 ± 255.470 | 83.97 ± 25.386 | 81.05 ± 19.743 | 43.92 ± 157.676 |
| Day 19 at 3 hour | 69.18 ± 58.761 | 48.51 ± 73.341 | 23.64 ± 228.479 | 81.62 ± 33.415 | 78.01 ± 26.265 | 14.85 ± 263.930 |
| Day 19 at 6 hour | 60.96 ± 72.629 | 50.21 ± 77.242 | 51.59 ± 126.753 | 82.98 ± 29.512 | 70.87 ± 35.515 | 58.64 ± 105.239 |
| Day 19 at 12 hour | 1.08 ± 313.927 | 33.43 ± 110.105 | 36.92 ± 204.360 | 84.45 ± 25.743 | 44.97 ± 112.099 | 13.17 ± 215.066 |
| Day 19 at 18 hour | 69.69 ± 57.918 | 74.55 ± 46.130 | 15.41 ± 281.253 | 91.12 ± 4.541 | 88.43 ± 10.953 | 84.46 ± 28.685 |
| Day 19 at 24 hour | 89.86 ± 13.568 | 80.90 ± 28.329 | 29.02 ± 230.055 | 83.67 ± 34.194 | 82.63 ± 20.393 | 71.27 ± 57.042 |
Inhibition of plasma TXB2 at each time point were calculated using the percentage of reduction from baseline as follows: Inhibition (%) = 100 × (Baseline Value - Post-baseline Value) / Baseline Value. For primary analysis, the mean and the lower bound of the corresponding one-sided 95% CI were calculated.
| percentage | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid |
|---|---|---|---|---|---|---|
| Day 7 at 1 hour | 98.84 (98.35 to NA) | 98.82 (98.33 to NA) | 97.59 (96.62 to NA) | 98.34 (97.61 to NA) | 99.40 (99.17 to NA) | 98.67 (98.14 to NA) |
| Day 7 at 3 hour | 97.82 (97.00 to NA) | 98.25 (97.48 to NA) | 97.72 (97.03 to NA) | 97.61 (96.55 to NA) | 98.95 (98.49 to NA) | 97.68 (96.44 to NA) |
| Day 7 at 6 hour | 97.95 (96.59 to NA) | 98.57 (97.83 to NA) | 98.37 (97.63 to NA) | 97.29 (96.46 to NA) | 99.06 (98.42 to NA) | 97.93 (97.29 to NA) |
| Day 7 at 12 hour | 97.75 (96.69 to NA) | 97.92 (96.72 to NA) | 96.66 (95.59 to NA) | 97.49 (96.71 to NA) | 98.54 (97.70 to NA) | 98.36 (97.52 to NA) |
| Day 7 at 18 hour | 97.85 (96.65 to NA) | 96.09 (94.63 to NA) | 98.79 (98.32 to NA) | 96.29 (94.83 to NA) | 97.97 (96.94 to NA) | 97.87 (96.98 to NA) |
| Day 7 at 24 hour | 96.62 (95.38 to NA) | 98.26 (97.59 to NA) | 98.89 (98.42 to NA) | 95.04 (93.35 to NA) | 98.13 (97.54 to NA) | 98.44 (97.81 to NA) |
| Day 16 at 1 hour | 98.06 (97.15 to NA) | 95.49 (93.79 to NA) | 89.55 (87.09 to NA) | 98.99 (98.59 to NA) | 96.73 (95.54 to NA) | 94.95 (92.99 to NA) |
| Day 16 at 3 hour | 93.03 (90.35 to NA) | 89.25 (85.98 to NA) | 92.62 (90.24 to NA) | 97.37 (96.45 to NA) | 96.17 (95.16 to NA) | 90.62 (87.59 to NA) |
| Day 16 at 6 hour | 93.55 (89.83 to NA) | 88.62 (83.96 to NA) | 90.40 (88.30 to NA) | 98.50 (97.89 to NA) | 95.56 (93.74 to NA) | 91.27 (87.89 to NA) |
| Day 16 at 12 hour | 89.55 (86.80 to NA) | 85.63 (80.50 to NA) | 88.76 (85.89 to NA) | 97.42 (96.77 to NA) | 92.30 (90.55 to NA) | 89.45 (84.52 to NA) |
| Day 16 at 18 hour | 86.61 (82.69 to NA) | 84.41 (80.03 to NA) | 82.14 (75.75 to NA) | 95.69 (94.57 to NA) | 93.28 (91.00 to NA) | 91.03 (87.81 to NA) |
| Day 16 at 24 hour | 86.42 (80.81 to NA) | 72.66 (65.53 to NA) | 77.71 (72.15 to NA) | 95.78 (94.35 to NA) | 88.49 (84.08 to NA) | 86.87 (81.86 to NA) |
| Day 17 at 1 hour | 86.19 (80.48 to NA) | 79.99 (74.59 to NA) | 86.14 (83.15 to NA) | 98.72 (98.30 to NA) | 93.75 (91.26 to NA) | 90.00 (84.47 to NA) |
| Day 17 at 3 hour | 85.45 (79.85 to NA) | 90.16 (87.39 to NA) | 92.60 (90.38 to NA) | 98.01 (97.13 to NA) | 88.52 (84.47 to NA) | 83.94 (78.25 to NA) |
| Day 17 at 6 hour | 82.90 (75.87 to NA) | 84.77 (80.99 to NA) | 83.08 (77.53 to NA) | 97.34 (96.57 to NA) | 92.39 (89.45 to NA) | 85.82 (79.55 to NA) |
| Day 17 at 12 hour | 83.49 (76.38 to NA) | 81.22 (75.88 to NA) | 86.50 (82.09 to NA) | 97.46 (96.40 to NA) | 92.42 (88.90 to NA) | 82.13 (76.07 to NA) |
| Day 17 at 18 hour | 85.77 (81.67 to NA) | 78.34 (72.79 to NA) | 86.53 (82.83 to NA) | 95.47 (93.79 to NA) | 85.70 (82.50 to NA) | 70.90 (62.89 to NA) |
| Day 17 at 24 hour | 79.55 (72.74 to NA) | 79.06 (72.89 to NA) | 75.67 (70.44 to NA) | 97.23 (96.19 to NA) | 92.07 (89.87 to NA) | 81.34 (76.55 to NA) |
| Day 19 at 1 hour | 92.68 (89.50 to NA) | 89.65 (86.17 to NA) | 95.32 (93.74 to NA) | 98.05 (97.37 to NA) | 94.39 (91.69 to NA) | 79.36 (73.75 to NA) |
| Day 19 at 3 hour | 91.03 (88.18 to NA) | 92.04 (90.13 to NA) | 93.68 (91.71 to NA) | 97.82 (97.16 to NA) | 94.53 (91.78 to NA) | 79.82 (74.39 to NA) |
| Day 19 at 6 hour | 90.57 (87.64 to NA) | 91.49 (88.95 to NA) | 92.35 (90.34 to NA) | 98.24 (97.66 to NA) | 93.72 (90.55 to NA) | 81.14 (77.02 to NA) |
| Day 19 at 12 hour | 91.59 (88.31 to NA) | 89.25 (86.51 to NA) | 95.18 (93.46 to NA) | 96.91 (95.87 to NA) | 92.84 (90.52 to NA) | 80.66 (75.32 to NA) |
| Day 19 at 18 hour | 91.20 (87.58 to NA) | 93.50 (91.00 to NA) | 94.85 (92.96 to NA) | 96.24 (95.27 to NA) | 92.74 (89.92 to NA) | 85.67 (81.17 to NA) |
| Day 19 at 24 hour | 93.76 (91.18 to NA) | 90.93 (87.80 to NA) | 93.66 (91.58 to NA) | 96.63 (95.39 to NA) | 96.14 (93.74 to NA) | 81.67 (74.94 to NA) |
Collected over Treatment emergent adverse events were collected after first dose of investigational product on Day 1 until completion of all study procedures throughout the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 0-IR ASA 81 mg qd in Run-in Period | — | 0/102 (0%) | 0/102 (0%) |
| Group 1-IR ASA Co-administered With Naproxen Sodium | — | 0/17 (0%) | 4/17 (23.5%) |
| Group 2-IR ASA 30 Min After Naproxen Sodium | — | 0/17 (0%) | 1/17 (5.9%) |
| Group 3-IR ASA 8 Hours After Naproxen Sodium | — | 0/17 (0%) | 4/17 (23.5%) |
| Group 4-IR ASA Only | — | 0/17 (0%) | 3/17 (17.6%) |
| Group 5-IR ASA 30 Min Before Naproxen Sodium | — | 0/17 (0%) | 2/17 (11.8%) |
| Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | — | 0/17 (0%) | 4/17 (23.5%) |
| Event | Group 0-IR ASA 81 mg qd in Run-in Period | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid |
|---|---|---|---|---|---|---|---|
| Infrequent bowel movementsGastrointestinal disorders | 0/102 | 0/17 | 0/17 | 1/17 | 1/17 | 0/17 | 2/17 |
| Ear painEar and labyrinth disorders | 0/102 | 1/17 | 0/17 | 0/17 | 0/17 | 0/17 | 0/17 |
| DiarrhoeaGastrointestinal disorders | 0/102 | 0/17 | 1/17 | 0/17 | 0/17 | 0/17 | 0/17 |
| Frequent bowel movementsGastrointestinal disorders | 0/102 | 0/17 | 1/17 | 0/17 | 0/17 | 0/17 | 0/17 |
| NauseaGastrointestinal disorders | 0/102 | 1/17 | 0/17 | 0/17 | 0/17 | 0/17 | 0/17 |
| Rectal haemorrhageGastrointestinal disorders | 0/102 | 0/17 | 0/17 | 0/17 | 0/17 | 0/17 | 1/17 |
| Chest discomfortGeneral disorders | 0/102 | 0/17 | 0/17 | 0/17 | 0/17 | 1/17 | 0/17 |
| FatigueGeneral disorders | 0/102 | 0/17 | 0/17 | 1/17 | 0/17 | 0/17 | 0/17 |
| Vessel puncture site bruiseGeneral disorders | 0/102 | 1/17 | 0/17 | 0/17 | 0/17 | 0/17 | 0/17 |
| ContusionInjury, poisoning and procedural complications | 0/102 | 0/17 | 0/17 | 1/17 | 0/17 | 0/17 | 0/17 |
| Age, Continuous(years) | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Non-Randomized | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 41.3 ± 8.46 | 31.2 ± 7.19 | 37.5 ± 13.41 | 34.2 ± 8.76 | 38.8 ± 12.09 | 38.9 ± 10.62 | 38.2 ± 13.74 | 37.1 ± 11.00 |
| Sex: Female, Male(Participants) | Group 1-IR ASA Co-administered With Naproxen Sodium | Group 2-IR ASA 30 Min After Naproxen Sodium | Group 3-IR ASA 8 Hours After Naproxen Sodium | Group 4-IR ASA Only | Group 5-IR ASA 30 Min Before Naproxen Sodium | Group 6-IR ASA 30 Min After First Dose of Naproxen Sodium Bid | Non-Randomized | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 7 | 4 | 6 | 4 | 4 | 7 | 4 | 36 |
| Male | 10 | 13 | 11 | 13 | 13 | 10 | 11 | 81 |
The record gives a start of Feb 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen